Small molecule RNA inhibitor shows promise in PCa
New research demonstrates that targeted treatment with a class of drugs called small molecule RNA inhibitors can successfully target and kill certain types of cancer, including prostate cancer.
In a recently published study, the treatment demonstrated promising activity for promoting apoptosis of prostate cancer cells in culture, reported investigators from Scripps Florida in a recently published study (ACS Cent Sci 2017; 3:205-16).
The compound, known as Targapremir-18a, inhibits the activity of microRNA-18, an oncogenic noncoding RNA that is overexpressed and causative in prostate cancer. Acting as a “dimmer switch,” microRNA-18 enables cancer cells to proliferate by circumventing the programmed cell death pathway.
In the in vitro experiment, the addition of Targapremir-18a to cultured DU145 prostate cancer cells resulted in increased synthesis of the proapoptic protein that corresponded to increased apoptotic cell death.